Finance Watch: Venture Capital Drives Record-Breaking Year For Cell And Gene Therapies

$8.2bn In VC Deals Through Q3 Is Up 45% Year-Over-Year

Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.

Finance Watch Private Company
• Source: Shutterstock

The Alliance for Regenerative Medicine reported on 22 November that cell and gene therapy companies have raised enough money already in 2021 to break the record set in 2020. Venture capital financings are driving the surge with $8.2bn raised through the third quarter, which is up 45% from the same nine-month period last year.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cell Therapies

  • Progress Or Hype? A Decade Of Cell Therapy In Japan

     
    • By 

    After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

  • Japan Cell Therapy Hopes Hit By HeartSheet Full Approval Hurdles

     
    • By 

    Despite initial promise, a novel autologous cell transplant therapy for severe heart failure has faced multiple challenges in gaining full approval in Japan, potentially providing learnings for other developers of regenerative medicines.

  • Quick Listen: Scrip's Five Must-Know Things

     
    • By 

    In this week's podcast edition of Five Must-Know Things: global CEO remuneration; another late-stage loss for Merch KgaA; deals shift to smaller M&A, partnering; Bayer’s Parkinson’s bets bear fruit; and India looks to innovate CAR-T models.

  • Bayer's Bets In Parkinson's Start To Bear Fruit

     
    • By 

    The German major is kicking off Phase II trials for a cell therapy and a gene therapy that could be gamechangers for the progressive neurodegenerative disorder that affects more than 10 million people worldwide.

More from Advanced Therapies